The review centers on CBX7, a member of the Chromobox protein family and a core subunit of Polycomb Repressive Complex 1, one of the two major Polycomb complexes that shape the epigenetic landscape of mammalian cells. Epigenetics, a field now seventy years old, concerns heritable changes in gene expression that occur without altering the underlying DNA sequence, chiefly through DNA methylation and histone modifications. Polycomb group proteins sit at the heart of this regulatory architecture, controlling cell fate decisions by modulating the expression of genes responsible for development, differentiation and, when things go wrong, cancer. Genome-wide studies have established that Polycomb Repressive Complex 1 and Polycomb Repressive Complex 2 function as crucial transcriptional regulators targeting a wide range of genes involved in tumor development, and the chromodomain-containing CBX proteins are the molecular anchors that tether Polycomb activity to specific chromatin regions.

Structurally, CBX7 is a study in molecular precision. Its chromodomain, spanning amino acids 9 to 48, descends from a conserved 37-amino acid sequence first identified in the Polycomb and heterochromatin protein 1 proteins of the fruit fly Drosophila melanogaster. Phylogenetic analyses show that the CBX7 chromodomain is more closely related to other Polycomb group proteins such as CBX2, CBX4, CBX6 and CBX8 than to the HP1 family members CBX1, CBX3 and CBX5, and unlike HP1 proteins, CBX7 lacks a chromoshadow domain. Instead, its chromodomain carries unique conserved residues exclusive to Polycomb proteins that are necessary for Polycomb dimer formation and for recognizing the tri-methylated lysine 27 mark on histone H3, known as H3K27me3. Thanks to the stable geometry of this domain, CBX7 preferentially binds H3K27me3, a mark laid down by the PRC2 complex through its core subunits EZH2, SUZ12 and EED. Once anchored, CBX7 recruits the canonical PRC1 complex, whose catalytic core ubiquitinates lysine 119 on histone H2A, compacting chromatin and silencing target genes. In this way, CBX7 acts as a functional bridge between PRC2 activity and stable transcriptional repression.

The protein also exists in two isoforms with strikingly divergent behavior. The 36-kilodalton nuclear form, p36CBX7, is expressed in proliferating cells and drives gene regulation, while the 22-kilodalton cytoplasmic form, p22CBX7, is induced by serum deprivation and restrains cell proliferation. This context- and tissue-specific duality foreshadows the protein’s complex role in cancer. Across human tumors, CBX7 behaves as either an oncogene or a tumor suppressor depending on the dominant signaling pathways and the genetic and epigenetic makeup of each tumor type. In lymphomas and gastric cancer, overexpressed CBX7 represses tumor-suppressive genes such as Ink4a/Arf and Trail, allowing malignant cells to evade senescence and apoptosis. In contrast, cancers of the breast, pancreas, lung, thyroid, colon, bladder and brain, including glioblastoma, consistently show reduced CBX7 expression compared with normal tissue, pointing to a tumor-suppressive function in these settings.

In glioblastoma specifically, the evidence for CBX7 as a tumor suppressor is compelling. High-grade gliomas exhibit significantly lower CBX7 levels than low-grade gliomas, and this downregulation correlates with aggressive disease and poor prognosis. When lost CBX7 is restored in glioma cells, tumor growth is inhibited and the cell cycle arrests at the G0/G1 phase. One well-characterized mechanism involves competition with the architectural transcription factor HMGA1 for control of the CCNE1 promoter, which encodes cyclin E1, a key driver of the G1/S transition. Under normal conditions, CBX7 partners with histone deacetylase 2 to form a repressive complex on the CCNE1 promoter. When CBX7 is lost, HMGA1 evicts this complex, cyclin E1 expression surges, and glioblastoma cells proliferate uncontrollably. HMGA1 also directly binds the CBX7 promoter itself, adding a further layer of antagonism.

The tumor-suppressive reach of CBX7 extends well beyond cell-cycle control into the machinery of invasion and stemness. CBX7 directly binds the promoter of CDH1, the gene encoding the adhesion molecule E-cadherin, where it restrains HDAC2 activity and promotes activating acetylation and methylation marks on histones H3 and H4, stabilizing the epithelial phenotype. Loss of CBX7 silences CDH1, promotes epithelial-to-mesenchymal transition and drives the invasiveness that typifies glioblastoma progression. CBX7 also prevents HMGA1 from transcriptionally activating SPP1, the gene encoding osteopontin, another potent EMT stimulator. Perhaps most strikingly, recent work shows that CBX7 engages PRC1 to facilitate ubiquitin-proteasome degradation of myosin heavy chain 9, thereby suppressing NF-kappaB signaling and stripping glioblastoma cells of their stem-like characteristics. Restoring MYH9 reverses this effect, re-establishing stemness, proliferation and invasion, and defining a CBX7-MYH9-NF-kappaB regulatory axis that researchers regard as a desirable therapeutic target.

Two further oncogenic pathways fall under CBX7’s control. The Wnt/beta-catenin pathway, aberrantly activated in many glioblastomas, is dampened when CBX7 binds the promoter of DKK1, a Wnt inhibitor, upregulating its expression and simultaneously reducing ZEB1, a transcription factor that promotes invasion, metastasis and epithelial-to-mesenchymal transition. Restoring CBX7 in glioblastoma cells suppresses both Wnt signaling and ZEB1, curtailing tumor growth and metastatic potential. CBX7 likewise modulates the Hippo pathway through connective tissue growth factor, encoded by CTGF, a key component of the YAP/TAZ signaling axis. When CBX7 is lost, PRC1-mediated gene suppression fails, YAP/TAZ signaling becomes hyperactive, TEAD-dependent transcription rises and CTGF is overexpressed, activating kinases such as SAPK/JNK and fueling glioma cell invasion and migration. Ectopic CBX7 expression additionally reduces the matrix metalloproteinases MMP2 and MMP9, major markers of glioblastoma invasiveness, angiogenesis and immune modulation.

How does such a critical tumor suppressor get silenced in the first place? The review details two principal mechanisms. The first is epigenetic: hypermethylation of the CBX7 promoter, confirmed by bisulfite sequencing in glioblastoma tissues, glioma-derived cell lines and normal brain, with clear enrichment of methylation in tumor samples. Knockdown studies identified the DNA methyltransferases DNMT1 and DNMT3A, but not DNMT3B, as the enzymes responsible for this silencing, and treatment with a methylation inhibitor restored CBX7 mRNA expression in glioma cell lines. The second mechanism is post-transcriptional, mediated by microRNAs. The MYC-responsive microRNA miR-9 lowers CBX7 protein levels, while CBX7 in turn binds the miR-9 promoter and represses its expression, creating an autoregulatory loop that also feeds into the control of p16-INK4a, a key effector of replicative senescence. Separately, the oncogenic miR-18a, highly expressed in glioblastoma, directly targets CBX7 mRNA, and silencing miR-18a in animal models markedly slows tumor growth and prolongs survival.

The translational implications are substantial, though tempered by caution. No CBX7-targeted therapy is yet in clinical use for glioblastoma, and the review’s authors stress that the protein’s role in normal cells must be fully understood before therapeutic modulation is attempted. Nevertheless, pharmacological proof of concept already exists in other malignancies: chromodomain-targeting inhibitors such as UNC3866, UNC4976, MS452, EC-134 and BDA-41 have dislodged overexpressed CBX7 from chromatin in lymphoid leukemia models, inducing differentiation and growth arrest. For glioblastoma, the therapeutic logic runs in the opposite direction, toward restoring rather than inhibiting CBX7 function, using epigenetic drugs, miRNA-based approaches or targeted modulation of CBX7-associated complexes and downstream pathways. Beyond therapy, CBX7’s consistent downregulation and correlation with tumor aggressiveness make it a promising prognostic biomarker, measurable through immunohistochemistry, methylation profiling or miRNA expression analysis to classify patients and guide treatment decisions. As the authors conclude, CBX7 represents a particularly promising starting point for developing more accurate and potent targeted treatments, and for deepening our understanding of glioblastoma biology in a disease that urgently needs both.

Subject of Research: The role of the Polycomb protein CBX7 as an epigenetic tumor suppressor in glioblastoma and its therapeutic potential.

Article Title: Epigenetic regulation by CBX7 in glioblastoma: molecular mechanisms and translational perspectives

Article References: Fayyaz, F., Favale, G., Capasso, L., Casalino, R., Mele, D., Verrilli, G., Conte, M., Carafa, V., Nebbioso, A., & Altucci, L. (2025). Epigenetic regulation by CBX7 in glioblastoma: molecular mechanisms and translational perspectives. Epigenetics Communications, 6(1), Article 2. https://doi.org/10.1186/s43682-025-00043-1

Image Credits: AI Generated

DOI: 10.1186/s43682-025-00043-1

Keywords: CBX7, glioblastoma, epigenetics, Polycomb, PRC1, PRC2, chromodomain, DNA methylation, microRNA, Wnt signaling, Hippo pathway, tumor suppressor

Meningiomas arise from the arachnoid cap cells of the meninges, the protective membranes enveloping the brain and spinal cord. Although the majority are classified as benign, WHO grade 1 tumors, their location within the confined space of the skull means that even slow growth can cause severe neurological impairment. Roughly half of patients undergo surgery simply to relieve pressure on the brain, and a substantial fraction of tumors recur after resection. Current classification relies on histopathological grading combined with limited molecular markers, chief among them mutations in the NF2 gene and alterations involving chromosomes 22 and 1p. But these markers correlate only loosely with clinical behavior, leaving oncologists unable to predict reliably which tumors will smolder and which will strike back.

The new research tackled this uncertainty by turning to DNA methylation, a chemical modification of cytosine bases in the genome that can switch genes on or off without altering the underlying DNA sequence. Methylation profiling has already transformed the diagnosis of gliomas and other brain tumors, providing a molecular fingerprint that often outperforms microscopic examination. The team applied high-resolution methylation arrays to large cohorts of meningioma samples spanning all WHO grades, from indolent grade 1 lesions to anaplastic grade 3 tumors, and asked a fundamental question: where in the genome does methylation change as tumors progress from harmless to lethal?

The answer pointed overwhelmingly to one genomic neighborhood. Clustered on chromosome 5q31, the protocadherin gene cluster comprises more than fifty genes arranged in three subfamilies — alpha, beta and gamma — spanning a stretch of DNA nearly a million base pairs long. These genes encode cell-surface proteins belonging to the cadherin superfamily, molecules that mediate cell-cell adhesion and are critically involved in neural development, axon guidance and the formation of synaptic connections. In healthy meningeal tissue, the cluster is active, expressing a combinatorial repertoire of protocadherin isoforms that helps cells recognize one another and maintain orderly tissue architecture. In progressing meningiomas, the researchers found, this entire region becomes progressively coated with methyl groups, effectively shutting down the cluster as if a master switch had been flipped.

What makes the discovery remarkable is the scale and logic of the silencing. Rather than individual genes being inactivated piecemeal, the methylation spreads in a long-range pattern across the entire locus, erasing the staggered, cell-type-specific expression patterns that normally allow each neuron or meningeal cell to display its own unique combination of protocadherins. The team’s analysis showed that this regional hypermethylation intensifies stepwise with tumor grade: grade 1 tumors show modest methylation, grade 2 tumors substantially more, and grade 3 tumors near-complete silencing. Crucially, the pattern was detectable even in tumors that had not yet acquired the histological features of malignancy, meaning the epigenetic clock of the tumor begins ticking before pathologists can see the damage.

The functional consequences of silencing the protocadherin cluster go to the heart of what makes a tumor dangerous. Protocadherins act as molecular barcodes that prevent cells from wandering; when they are lost, tumor cells gain the freedom to detach, migrate and invade surrounding brain tissue. The researchers demonstrated this experimentally by manipulating methylation in meningioma cell lines: pharmacological demethylation with DNA methyltransferase inhibitors restored protocadherin expression and reduced invasive behavior in vitro, while targeted re-expression of individual protocadherin genes suppressed cell migration and proliferation. Conversely, artificially silencing the genes in low-grade meningioma cells conferred a more aggressive phenotype. These gain- and loss-of-function experiments establish causality, not merely correlation — the epigenetic shutdown of the cluster is not a passenger event but an active engine of tumor progression.

The study also connected protocadherin silencing to existing molecular subtypes of meningioma. Tumors harboring NF2 mutations, which account for the majority of sporadic and radiation-induced cases, showed particularly pronounced methylation of the cluster, and the epigenetic signature outperformed conventional markers in predicting recurrence-free survival. When the authors integrated methylation data from the protocadherin locus into a predictive model, it stratified patients more accurately than WHO grade alone, correctly identifying a subset of histologically benign tumors that subsequently recurred and required additional treatment. This has immediate clinical implications: a methylation assay targeting the cluster could be incorporated into routine diagnostics, giving neurosurgeons and oncologists a sharper instrument for deciding which patients need close surveillance and adjuvant therapy and which can be spared it.

The mechanism behind the silencing appears to involve the canonical epigenetic machinery of cancer. Long-range methylation of the 5q31 region was accompanied by loss of the activating histone mark H3K4me3 and, in more advanced tumors, by recruitment of polycomb repressive complexes, which lock chromatin into a permanently closed configuration. The investigators found evidence that this is reinforced rather than random: once a threshold of methylation is crossed, the chromatin state becomes self-sustaining, explaining why silencing correlates so tightly with tumor grade and why it rarely reverses spontaneously. The clustered protocadherins thus join a growing list of tumor-suppressive epigenetic targets — alongside genes such as CDKN2A and RASSF1A — but with the distinction that an entire megabase-scale gene family, rather than a single locus, is affected.

Therapeutically, the findings open two avenues. The first is pharmacological: DNA demethylating agents such as decitabine and azacitidine are already approved for hematological malignancies, and the study’s cell-line experiments suggest they can reactivate the protocadherin cluster in meningioma cells. Delivering such drugs to the central nervous system remains a challenge, but the results provide a clear proof of principle that the epigenetic lesion is chemically reversible. The second avenue is more speculative but intriguing: because protocadherins sit on the cell surface, they are accessible to antibodies or engineered binding proteins, raising the possibility that future therapies could bypass the silenced genes entirely by supplying or mimicking the adhesion signals the tumor has lost.

Independent experts in neuro-oncology, while not involved in the study, note that it fits into a broader shift in brain tumor medicine toward epigenetics as both diagnostic compass and therapeutic target. The classification of diffuse gliomas was revolutionized by the discovery of IDH mutations and their associated methylation signatures, and methylation profiling is now standard practice in many neuropathology laboratories. Extending that framework to meningiomas — the most common tumor neurosurgeons encounter — could standardize what has until now been a subjective exercise in histological grading. It also highlights a recurring theme in cancer biology: the genome tells only half the story, and the regulatory layer written in methyl groups and histone marks often determines whether a tumor is manageable or malignant.

The research team, led by investigators based in Germany with collaborators across Europe, assembled one of the largest methylation datasets yet compiled for meningioma, combining retrospective tumor banks with matched long-term clinical follow-up. That combination allowed the authors to demonstrate that the epigenetic signature measured at the time of initial surgery predicted patient outcomes years in advance. The next steps will involve prospective validation in independent patient cohorts, standardization of the assay for clinical laboratories, and preclinical testing of demethylating strategies in animal models of meningioma. If those efforts succeed, patients facing a meningioma diagnosis may one day receive not just a grade but a genuinely predictive molecular forecast — and, for those whose tumors carry the silenced protocadherin signature, a treatment aimed at the root epigenetic cause rather than merely the surgical removal of its consequences.

For now, the study stands as a striking example of how a genome-wide, unbiased search for methylation changes can converge on a single biological mechanism with profound clinical relevance. More than fifty genes, silenced together across a million bases of DNA, determine whether a tumor of the brain’s protective lining will behave itself or turn lethal. In revealing that mechanism, the work transforms our understanding of meningioma progression and adds a powerful new tool to the molecular toolkit of neuro-oncology.